You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. DEVELOPMENT OF ANTIHEPATITIS B THERAPEUTICS

    SBC: Oxford Glycosystems, Inc.            Topic: N/A

    Oxford GlycoSystems (OGS) will evaluated two novel types of anti- hepatitis (HB) drugs: Anti-HB drugs conjugates with glycans - Using one-step conjugations adaptable to large-scale manufacturing, OGS is derivitizing anti-retroviral drugs (eg vidarabine, Ara-C, acyclovir, AZT, lamivudine) with glycans recognized by hepatocyte carbohydrate receptors. Similar compounds are targets with high specific ...

    SBIR Phase I 1997 Department of Health and Human Services
  2. Development of Artificial, Collagen Based Corneal Grafts

    SBC: Autogenesis Technologies, Inc.            Topic: N/A

    The objective is to develop an artificial full-thickness corneal graft to replace damaged corneain millions of people who suffer from blindness due to damaged or diseased cornea. The specific aimsof Phase I are to fabricate prototype grafts composed of a clear, soluble collagen core surrounded by aperipheral ring, or skirt, containing' intact collagen fibers embedded in soluble collagen. Prelimina ...

    SBIR Phase I 1994 Department of Health and Human Services
  3. DEVELOPMENT OF A SCREEN FOR BACTERIAL RNASE P INHIBITORS

    SBC: CUBIST PHARMACEUTICALS, INC.            Topic: N/A

    The need for novel antibiotics has never been greater. Infectious diseases are the third cause of death in the US, and their toll is increasing, with a 580/0 increase in mortality from 1980 to 1992. A large reason for this rise is the evolution and spread of antibiotic- resistant bacteria. We plan to combat this rise in antibiotic resistance by identifying inhibitors of novel bacterial targets to ...

    SBIR Phase I 1997 Department of Health and Human Services
  4. DEVELOPMENT OF A TRANSGENIC RAT ATHEROSCLEROSIS MODEL

    SBC: T CELL SCIENCES, INC.            Topic: N/A

    N/A

    SBIR Phase I 1996 Department of Health and Human Services
  5. Development of Audiometric Localization Tests

    SBC: SENSIMETRICS CORP            Topic: N/A

    N/A

    SBIR Phase I 1994 Department of Health and Human Services
  6. DEVELOPMENT OF A VACCINE FOR CLOSTRIDIUM DIFFICILE

    SBC: Oravax, Inc.            Topic: N/A

    N/A

    SBIR Phase I 1996 Department of Health and Human Services
  7. DEVELOPMENT OF A VIRUS FREE FIBRIN GLUE

    SBC: APHIOS CORPORATION            Topic: N/A

    N/A

    SBIR Phase I 1996 Department of Health and Human Services
  8. Development of Caco-2 Cells Expressing Cytochromes P450

    SBC: GENTEST CORPORATION            Topic: N/A

    N/A

    SBIR Phase I 1995 Department of Health and Human Services
  9. Development of Calcification Resistant Valve Prosthesis

    SBC: ABIOMED, INC.            Topic: N/A

    Calcification of blood contacting surfaces has been the key impediment to the development of polymevalve prostheses and other polymeric implantables. The deposition of calcium plaques as hydroxyapatiand potentially leads to valve dysfunction. That calcification proceeds preferentially along surfacestress only exacerbates the problem. This work is based on the hypothesis that calcification along fa ...

    SBIR Phase I 1995 Department of Health and Human Services
  10. Development of Chemokines for Myeloprotection

    SBC: REPLIGEN CORPORATION            Topic: N/A

    We will develop a myelostatic agent to protect human hematopoietic precursor cells from the destrucchemotherapeutic agents currently used in the treatment of tumors. We propose that protection of preinhibition of growth during cancer treatment would reduce the toxicity associated with standard chemadministration of higher doses of chemotherapeutics without compromising the ability of the patientfu ...

    SBIR Phase I 1995 Department of Health and Human Services
US Flag An Official Website of the United States Government